• Sarepta Exercises Option to Acquire Myonexus Therapeutics pharmafocusasia
    March 14, 2019
    Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, announced today that it has exercised its option to acquire Myonexus Therapeutics, a clinical-stage biotechnology company developing transformative gene ...
  • Sarepta adds muscular dystrophy gene therapies via Myonexus pact fiercebiotech
    May 07, 2018
    Sarepta is determined to stay at the forefront of genetic medicines for muscular dystrophies and to that end has signed another R&D deal—this time with Myonexus Therapeutics—and taken an option on buying the company.
PharmaSources Customer Service